FOXO news

FOXO Technologies Inc. signed agreements to acquire preferred stock carrying majority voting power and certain notes from Ludwig Enterprises. Ludwig is developing a non-invasive mRNA biomarker testing platform called Revealia.

FOXO Technologies Inc.'s subsidiary Vector Biosource announced the acquisition of four US blood collection centers to source bio-products and expand market access. Closing is required by 2026.

FOXO Technologies submitted an 8-K filing containing an agreement (Exhibit 10.1) with certain schedules and exhibits omitted as non-material per SEC regulations. The company committed to furnishing omitted materials to the SEC upon request.

FOXO Technologies submitted an exhibit document as part of SEC 8-K filing disclosure requirements. The specific contract terms and financial implications require full document review for market impact assessment.